Trial record 45 of 117 for: "Connective Tissue Disease" | "Methylprednisolone"
Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02466581|
Recruitment Status : Recruiting
First Posted : June 9, 2015
Last Update Posted : December 4, 2018
Information provided by (Responsible Party):
Ronald van Vollenhoven, prof., Karolinska Institutet
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||December 2021|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Glinatsi D, Heiberg MS, Rudin A, Nordström D, Haavardsholm EA, Gudbjornsson B, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, van Vollenhoven R, Hetland ML. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials. 2017 Apr 4;18(1):161. doi: 10.1186/s13063-017-1891-x.